Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Intangibles (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Intangibles for 6 consecutive years, with $440000.0 as the latest value for Q4 2025.

  • Quarterly Intangibles fell 96.99% to $440000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $440000.0 through Dec 2025, down 96.99% year-over-year, with the annual reading at $440000.0 for FY2025, 96.99% down from the prior year.
  • Intangibles hit $440000.0 in Q4 2025 for Insight Molecular Diagnostics, roughly flat from $440000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $94.7 million in Q1 2022 to a low of $440000.0 in Q1 2023.
  • Historically, Intangibles has averaged $39.2 million across 5 years, with a median of $47.4 million in 2021.
  • Biggest five-year swings in Intangibles: tumbled 99.54% in 2023 and later skyrocketed 12757.5% in 2024.
  • Year by year, Intangibles stood at $61.9 million in 2021, then changed by 0.0% to $61.9 million in 2022, then crashed by 99.29% to $440000.0 in 2023, then surged by 3219.77% to $14.6 million in 2024, then tumbled by 96.99% to $440000.0 in 2025.
  • Business Quant data shows Intangibles for IMDX at $440000.0 in Q4 2025, $440000.0 in Q3 2025, and $440000.0 in Q2 2025.